The company has developed a therapy treatment for solid tumours based on research at the City of Hope Cancer Centre in Los Angeles. Known as CLTX-CAR T the therapy uses chlorotoxin, a peptide discovered in scorpion venom, to reprogram a patient’s T cells to target cancer cells. The therapy is currently undergoing phase one clinical trials at the City of Hope Cancer Centre in treating glioblastoma, an aggressive form of brain cancer. A type of immunotherapy, CAR T cell treatment is short for Chimeric Antigen Receptor T-cell therapy. It involves taking some of a patient’s white blood cells, re-engineers these in a laboratory to more effectively target cancer cells, and re-injects them into the patient.
